NIH Guide: Weekly Index for June 5, 2020

Funding Opportunities

• Mid-Career Enhancement Awards to Integrate Basic Behavioral, Biomedical, and/or Social Scientific Processes (K18 No Independent Clinical Trials)
  (PAR-20-211)
  NIH Basic Behavioral and Social Science Opportunity Network
  National Institute on Alcohol Abuse and Alcoholism
  National Cancer Institute
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  Office of Behavioral and Social Sciences Research
  National Institute on Minority Health and Health Disparities
  Application Receipt Date(s): March 17, 2021, March 17, 2022, March 17, 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• National Institute of General Medical Sciences Institutional Predoctoral Research Training Grant (T32 - Clinical Trial Not Allowed)
  (PAR-20-213)
  National Institute of General Medical Sciences
  Application Receipt Date(s): Standard dates apply All applications are due by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional)
  (PAR-20-221)
  National Institute on Drug Abuse
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
• Enhancing Science, Technology, EnginEering, and Math Educational Diversity (ESTEEMED) Research Education Experiences (R25)
  (PAR-20-223)
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): June 24, 2020; June 24, 2021; June 24, 2022
• Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional)
  (PAR-20-224)
  National Institute on Drug Abuse
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below
• Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)
  (PAR-20-225)
  National Institute on Drug Abuse
  Application Receipt Date(s): November 2, 2020, October 19, 2021, October 19, 2022 by 5:00 PM local time of applicant organization. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Mid-Career Enhancement Awards to Integrate Basic Behavioral, Biomedical, and/or Social Scientific Processes (K18 Basic Experimental Studies with Humans Required)
  (PAR-20-226)
  NIH Basic Behavioral and Social Science Opportunity Network
  National Institute on Alcohol Abuse and Alcoholism
  National Cancer Institute
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  Office of Behavioral and Social Sciences Research
  National Institute on Minority Health and Health Disparities
  Application Receipt Date(s): March 17, 2021, March 17, 2022, March 17, 2023, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Alcohol-HIV/AIDS Program Project Comorbidities, Coinfections, and Complications Research: Intervention and Cross-Cutting Foundational Research (P01 Clinical Trial Optional)
  (RFA-AA-20-009)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date listed below.
• Emergency Awards: SARS-CoV-2 Serological Sciences Centers of Excellence (U54 Clinical Trial Optional)
  (RFA-CA-20-038)
  National Cancer Institute
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): July 22, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. No late applications will be accepted for this FOA.
• Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional)
  (RFA-CA-20-039)
  National Cancer Institute
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): July 22, 2020
• Advancing HIV/AIDS Research through Computational Neuroscience FOA (R01 - Clinical Trial Optional)
  (RFA-DA-21-013)
  National Institute on Drug Abuse
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
• George M. O'Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional)
  (RFA-DK-20-008)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): November 4, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Advancing Genomic Medicine Research (Clinical Trial Optional) (R01)
  (RFA-HG-20-036)
  National Human Genome Research Institute
  Application Receipt Date(s): August 3, 2020; March 8, 2021; November 2, 2021; August 1, 2022; March 13, 2023. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Advancing Genomic Medicine Research (Clinical Trial Optional) (R21)
  (RFA-HG-20-037)
  National Human Genome Research Institute
  Application Receipt Date(s): August 3, 2020; March 8, 2021; November 2, 2021; August 1, 2022; March 13, 2023. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 Clinical Trial Required)
  (RFA-HL-21-003)
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Eye Institute
  National Institute of Neurological Disorders and Stroke
  National Center for Advancing Translational Sciences
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): October 2, 2020